Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST COVID-19 treatment trial
ISRCTN40580903Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of gemtuzumab ozogamicin, namilumab and infliximab in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (4 arms), sponsored by University of Birmingham. Primary endpoint: C-reactive protein levels. Started May 2020; status: completed.
02
Drugs
gemtuzumab ozogamicinnamilumabinfliximab
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ISRCTN40580903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40580903.